Latest Breaking News On - Clinical global impression - Page 16 : comparemela.com

Novel Treatment for Adult ADHD

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

United statesNew yorkFeng yuNational institute of mental healthDepartment of psychiatryStanley medical research instituteHealth behavior at augusta universityUs food drug administrationNat incAugusta universityDrug administrationSymptom rating scaleClinical global impressionGlobal assessmentEpworth sleepiness scalePittsburgh sleep quality index

HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal.

United statesJeffreym daynoLuis sanayKumar budurDrug administrationServices sociaux du saguenayCompany nasdaqParagon biosciencesMyotonic dystrophy health indexCentre intPrnewswire harmony biosciences holdings incExchange commissionBiosciences holdingsDaytime sleepiness scaleFatigue severity scaleEpworth sleepiness scale

Harmony Biosciences (HRMY) Announces Positive Topline Data From Phase 2 Signal Detection Study Evaluating Pitolisant In Adult Patients With Myotonic Dystrophy Type 1

Harmony Biosciences (HRMY) Announces Positive Topline Data From Phase 2 Signal Detection Study Evaluating Pitolisant In Adult Patients With Myotonic Dystrophy Type 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jeffreym daynoKumar budurJean denis brissonServices sociaux du saguenayHarmony biosciences holdings incMyotonic dystrophy health indexCentre intCompany nasdaqHarmony biosciences holdingsDaytime sleepiness scaleFatigue severity scaleEpworth sleepiness scaleClinical global impressionUniversitaire de santChief medical officerOpen label extension

Harmony Biosciences Holdings, Inc Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1

Harmony Biosciences Holdings, Inc. announced positive topline results from its Phase 2 signal detection study evaluating the safety and efficacy of pitolisant in adult patients with myotonic dystrophy.

United statesMyotonic dystrophy health indexDrug administrationHarmony biosciences holdings incHarmony biosciences holdingsDaytime sleepiness scaleFatigue severity scaleEpworth sleepiness scaleClinical global impressionOpen label extensionMyotonic dystrophy typeFourth quarter

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA

United kingdomUnited statesBritish columbiaIan mortimerJodi regtsChristopher kenneyXenon pharmaceuticals incExchange commissionXenon pharmaceuticalsSecurities exchangeAmerican epilepsy societyDepression rating scaleHamilton depression rating scaleSnaith hamilton pleasure scaleClinical global impressionChief medical officer